NCT06543381 2026-03-05Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell TransplantCity of Hope Medical CenterPhase 1 Recruiting15 enrolled
NCT06566742 2026-03-04A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.M.D. Anderson Cancer CenterPhase 2 Recruiting15 enrolled